Google Advertisement
Michigan, September 16, 2026 – Abbott Laboratories has agreed to pay nearly US$385 million to settle allegations that its powdered infant formula was produced under unsafe conditions, marking one of the largest food safety related penalties in U.S. history.
The settlement, announced by the Department of Justice, resolves claims tied to Abbott’s Sturgis, Michigan facility, which was at the center of contamination concerns that shook the infant nutrition industry in 2022.
The government alleged that between 2018 and 2022, Abbott failed to comply with federal and state safety standards, exposing its formula to risks of microorganism contamination.
The case also highlighted lapses in transparency, with accusations that the company concealed safety issues while continuing to supply formula to government programs.
Google Advertisement
The settlement covers products purchased through Medicaid and the Women, Infants, and Children (WIC) program, which together account for more than half of all infant formula consumed in the United States.
Justice Department officials framed the agreement as a victory for families, stressing that food safety for infants is “nonnegotiable.”
The penalty underscores Washington’s growing determination to hold corporations accountable when essential goods are compromised.
“Parents should never have to question whether the formula they feed their babies is safe,” the DOJ said in its statement.
Abbott, while agreeing to the payout, denied liability.
The company emphasized that no unopened distributed formula tested positive for Cronobacter sakazakii during the 2022 recall, and insisted that its products remain safe.
Still, the reputational damage is significant.
Abbott was already under fire during the nationwide formula shortage in 2022, when the Sturgis plant shutdown exacerbated supply chain fragility and left families scrambling for alternatives.
Economically, the settlement is expected to weigh on Abbott’s margins, particularly in its consumer health division.
Analysts note that the payout, while manageable for a company of Abbott’s size, signals heightened regulatory risk for the entire industry.
Competitors may face stricter audits and compliance costs, but the broader effect could be improved safety standards across the sector.
For policymakers, the case highlights vulnerabilities in America’s reliance on a handful of formula producers.
The settlement may accelerate efforts to diversify supply chains and strengthen FDA oversight.
For parents, the episode reinforces the importance of transparency and accountability in products that are vital to infant health.
Abbott’s agreement closes a painful chapter but leaves lingering questions about trust in the industry.
As regulators tighten their grip, the settlement stands as a warning that lapses in safety will carry heavy consequences not just in financial terms, but in public confidence.
